GBT
ALNY icon

Grove Bank & Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Grove Bank & Trust’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.21K Sell
14
-28
-67% -$8.45K ﹤0.01% 749
2026
Q1 		$13.9K Buy
42
+33
+367% +$11.2K ﹤0.01% 583
2025
Q4 		$3.58K Buy
+9
New +$3.98K ﹤0.01% 761
2023
Q2 		– Sell
-6
Closed -$1.2K – 639
2023
Q1 		$1.2K Buy
+6
New +$1.26K ﹤0.01% 688

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Grove Bank & Trust's ALNY Position: Q2 2026 in Review

Grove Bank & Trust reduced its Alnylam Pharmaceuticals (ALNY) stake by 67% in Q2 2026, selling an estimated $8.45K and leaving 14 shares worth $4.21K. The position accounts for ﹤0.01% of the portfolio, ranked #749.

Grove Bank & Trust first reported a position in ALNY in Q1 2023 and has held it in 4 quarters since. The position peaked at $13.9K in Q1 2026. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Grove Bank & Trust held 14 shares of Alnylam Pharmaceuticals worth $4.21K as of Q2 2026.
  • Grove Bank & Trust sold 28 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $8.45K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Grove Bank & Trust's portfolio in Q2 2026, its #749 holding.
  • Grove Bank & Trust first reported a position in Alnylam Pharmaceuticals in Q1 2023 and has held it in 4 quarters since.
  • Grove Bank & Trust's Alnylam Pharmaceuticals position peaked at $13.9K in Q1 2026.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.